SAB Biotherapeutics Statistics
Share Statistics
SAB Biotherapeutics has 9.23M shares outstanding. The number of shares has increased by 0.04% in one year.
| Shares Outstanding | 9.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 7.44M |
| Failed to Deliver (FTD) Shares | 1.74K |
| FTD / Avg. Volume | 1.69% |
Short Selling Information
The latest short interest is 56.42K, so 0.61% of the outstanding shares have been sold short.
| Short Interest | 56.42K |
| Short % of Shares Out | 0.61% |
| Short % of Float | 0.75% |
| Short Ratio (days to cover) | 0.62 |
Valuation Ratios
The PE ratio is -0.9 and the forward PE ratio is -1.28.
| PE Ratio | -0.9 |
| Forward PE | -1.28 |
| PS Ratio | 16.97 |
| Forward PS | 19.7 |
| PB Ratio | 0.66 |
| P/FCF Ratio | -1.5 |
| PEG Ratio | n/a |
Enterprise Valuation
SAB Biotherapeutics Inc. has an Enterprise Value (EV) of -12.67M.
| EV / Earnings | 0.3 |
| EV / Sales | -5.66 |
| EV / EBITDA | 0.33 |
| EV / EBIT | 0.33 |
| EV / FCF | 0.5 |
Financial Position
The company has a current ratio of 5.45, with a Debt / Equity ratio of 0.1.
| Current Ratio | 5.45 |
| Quick Ratio | 5.45 |
| Debt / Equity | 0.1 |
| Total Debt / Capitalization | 9.35 |
| Cash Flow / Debt | -4.25 |
| Interest Coverage | -120.77 |
Financial Efficiency
Return on equity (ROE) is -0.74% and return on capital (ROIC) is -60.24%.
| Return on Equity (ROE) | -0.74% |
| Return on Assets (ROA) | -0.5% |
| Return on Capital (ROIC) | -60.24% |
| Revenue Per Employee | 39.28K |
| Profits Per Employee | -740.24K |
| Employee Count | 57 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -40.8% in the last 52 weeks. The beta is 0.64, so SAB Biotherapeutics 's price volatility has been higher than the market average.
| Beta | 0.64 |
| 52-Week Price Change | -40.8% |
| 50-Day Moving Average | 3.6 |
| 200-Day Moving Average | 3.26 |
| Relative Strength Index (RSI) | 46.48 |
| Average Volume (20 Days) | 102.79K |
Income Statement
In the last 12 months, SAB Biotherapeutics had revenue of 2.24M and earned -42.19M in profits. Earnings per share was -7.64.
| Revenue | 2.24M |
| Gross Profit | -1.51M |
| Operating Income | -38.08M |
| Net Income | -42.19M |
| EBITDA | -38.13M |
| EBIT | -38.08M |
| Earnings Per Share (EPS) | -7.64 |
Balance Sheet
The company has 56.57M in cash and 5.91M in debt, giving a net cash position of 50.66M.
| Cash & Cash Equivalents | 56.57M |
| Total Debt | 5.91M |
| Net Cash | 50.66M |
| Retained Earnings | -90.06M |
| Total Assets | 53.80M |
| Working Capital | 23.72M |
Cash Flow
In the last 12 months, operating cash flow was -25.12M and capital expenditures -197.15K, giving a free cash flow of -25.32M.
| Operating Cash Flow | -25.12M |
| Capital Expenditures | -197.15K |
| Free Cash Flow | -25.32M |
| FCF Per Share | -4.59 |
Margins
Gross margin is -67.28%, with operating and profit margins of -1.70K% and -1.88K%.
| Gross Margin | -67.28% |
| Operating Margin | -1.70K% |
| Pretax Margin | -1.88K% |
| Profit Margin | -1.88K% |
| EBITDA Margin | -1.70K% |
| EBIT Margin | -1.70K% |
| FCF Margin | -1.13K% |
Dividends & Yields
SABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -214.01% |
| FCF Yield | -76.93% |
Analyst Forecast
The average price target for SABS is $9.5, which is 166.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 166.1% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Jan 5, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jan 5, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -3.95 |
| Piotroski F-Score | 2 |